on Eckert & Ziegler Strahlen- Und Medizintechnik AG (isin : DE0005659700)
Eckert & Ziegler Achieves Significant Growth in First Half of 2024
Berlin, 9 August 2024. Eckert & Ziegler SE reported a notable increase in sales and earnings for the first half of 2024. Sales surged by 23% to €145.4 million compared to the same period last year. EBIT before special items grew to €32.5 million, while net profit rose 65% to €18.0 million.
The Medical segment experienced a 32% increase in sales, reaching €69.7 million, driven by pharmaceutical radioisotopes and plant engineering. The Isotope Products segment also saw a rise in sales, totaling €75.7 million, benefiting from shifts towards higher-margin products.
The company confirmed its forecast for 2024, projecting sales close to €265 million and an adjusted EBIT of around €55 million.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news